Dose Ranging and Dose Frequency of LIPO-102

Phase 2CompletedNCT00918814

Neothetics, Inc54 enrolled

Overview

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Subcutaneous Adipose Tissue Reduction

Interventions

LIPO-102DRUG

Subcutaneous Injection

PlaceboDRUG

Placebo

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male or non pregnant female * Good general health * Sufficient abdominal fat for injections * Signed informed consent Exclusion Criteria: * Known hypersensitivity to study drugs * Treatment with an investigational agent within 30 days of first dose

Locations (2)

Unnamed facility

San Diego, California, United States

Unnamed facility

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Safety: physical examinations, laboratory tests, AE assessment

Time frame: 4 weeks treatment and 4 weeks follow up

Secondary Outcomes

Efficacy: change in subcutaneous abdominal adipose tissue thickness

Time frame: 4 weeks treatment and 4 weeks follow up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.